Table 4.
New-Onset Categorical Glucose and Lipid Metabolism Outcomes
| Outcome Variable | Total (n=272) |
Aripiprazole (n=41) |
Olanzapine (n=45) |
Quetiapine (n=36) |
Risperidone (n=135) |
Comparison Group (n=15) |
P-Value including the Comparison Group |
P-Value excluding the Comparison Group a |
|---|---|---|---|---|---|---|---|---|
| Weight Loss - n (%) | 16 (5.9) | 2 (4.9) | 1 (2.2) | 1 (2.8) | 6 (4.4) | 6 (40.0) | <0.001 | 0.83 |
| Weight Gain ≥7% - n (%) | 169 (62.1) | 24 (58.4) | 38 (84.4) | 20 (55.6) | 87 (64.4) | 0 (0.0) | <0.001 | <0.05 |
| Weight Gain ≥14% - n (%) | 75 (27.6) | 7 (17.1) | 23 (51.1) | 11 (30.6) | 34 (25.2) | 0 (0.0) | 0.03 | 0.01 |
| Weight Gain ≥21% - n (%) | 24 (8.8) | 2 (4.9) | 11 (24.4) | 2 (5.6) | 9 (6.7) | 0 (0.0) | 0.002 | 0.01 |
| Transition to overweight b or obese c category - n (%) | 47 (17.3) | 4 (9.8) | 10 (22.2) | 13 (36.1) | 19 (14.1) | 1 (6.6) | 0.0092 | 0.04 |
| >10% BMI - n (%) | 101 (37.1) | 9 (22.0) | 30 (66.7) | 14 (38.9) | 48 (35.6) | 0 (0.0) | <0.001 | 0.003 |
| >20% BMI - n (%) | 23 (8.5) | 3 (7.3) | 10 (22.2) | 2 (5.6) | 8 (5.9) | 0 (0.0) | 0.007 | 0.12 |
| >0.5 BMI z-Score- n (%) | 114 (41.9) | 9 (22.0) | 28 (62.2) | 13 (36.1) | 64 (47.4) | 0 (0.0) | <0.001 | 0.03 (ARI) 0.04 (OLA) |
| >1.0 BMI z-Score- n (%) | 49 (18.1) | 2 (4.9) | 16 (35.6) | 5 (13.9) | 26 (19.3) | 0 (0.0) | 0.001 | 0.04 |
| Hyperglycemia d, e (>100 mg/dL) – no. (%) | 9 (3.4) | 2 (4.9) | 1 (2.2) | 2 (5.9) | 4 (3.0) | 0 (0.0) | 0.79 | 0.86 |
| Hyperinsulinemia d (≥ 20 U/mL) - no. (%) | 21 (7.9) | 3 (7.3) | 8 (17.8) | 1 (2.9) | 9 (6.8) | 0 (0.0) | 0.07 | 0.03 |
| Insulin Resistance d (HOMA IR≥4.4 | 23 (8.6) | 3 (7.3) | 8 (17.8) | 1 (2.9) | 11 (8.3) | 0 (0.0) | 0.10 | 0.02 |
| Hypercholesterolemia f - (≥170 mg/dL) - no. (%) | 35 (13.0) | 3 (7.3) | 12 (26.7) | 5 (14.7) | 23 (17.2) | 0 (0.0) | 0.06 | 0.26 |
| High LDL-cholesterol f - (>110 mg/dL) - no. (%) | 34 (12.6) | 2 (4.9) | 13 (28.9) | 5 (14.7) | 13 (9.7) | 1 (6.7) | 0.03 | 0.006 |
| Low HDL-cholesterol f (<40 mg/dL) no. (%) | 13 (4.8) | 2 (4.9) | 5 (11.1) | 2 (5.9) | 4 (3.0) | 0 (0.0) | 0.22 | 0.37 |
| Hypertriglyceridemia f - (≥110 mg/dL) no. (%) | 35 (13.0) | 3 (7.3) | 9 (20.0) | 6 (11.9) | 16 (12.0) | 1 (6.7) | 0.35 | 0.18 |
| Dyslipidemia f - (cholesterol ≥170 mg/dL and/or triglycerides ≥110 mg/dL) - no. (%) | 46 (17.1) | 3 (7.3) | 13 (28.9) | 3 (8.8) | 26 (19.3) | 1 (6.7) | 0.03 | 0.04 |
| Triglyceride/HDL ratio ≥3.5 e - no. (%) | 23 (8.6) | 3 (7.3) | 5 (11.1) | 4 (11.8) | 11 (8.2) | 0 (0.0) | 0.68 | 0.49 |
| Metabolic syndrome g - no. (%) | 4 (1.6) | 1 (2.5) | 1 (2.5) | 2 (6.5) | 0 (0.0) | 0 (0.0) | 0.13 | 0.44 |
Bolded p values: <0.05
Controlled for each respective baseline value (BMI z score for categorical shift in body composition parameters; BMI percentile for upward shift in weight category), as well as sex, baseline GAF score and mood stabilizer and anticholinergic cotreatment
At-risk weight category: ≥85th-<95th BMI percentile
Overweight category: ≥95th BMI percentile
Percentages are based on the number of patients with data available: 41 in the aripiprazole group, 45 in the olanzapine group, 34 in the quetiapine group, 134 in the risperidone group and 14 in the control group
one premorbidly obese adolescent developed diabetes mellitus while receiving quetiapine.
Percentages are based on the number of patients with data available: 41 in the aripiprazole group, 45 in the olanzapine group, 34 in the quetiapine group, 133 in the risperidone group and 14 in the control group
Percentages are based on the number of patients with data available: 40 in the aripiprazole group, 40 in the olanzapine group, 31 in the quetiapine